secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0001628280-24-045022
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera Q3 net loss widens to $51.1M as expenses rise; revenue flat at $6.5M
------------------------------------------------------------------------------

- Revenue $6.5M, flat QoQ and YoY; net loss $51.1M ($0.17/share) vs $28.6M ($0.10/share) in Q3 2023.
- R&D expenses rose to $41.0M from $37.9M; G&A expenses increased to $19.1M from $14.4M.
- Cumulative partner programs with downstreams reached 95 (up 13% YoY); molecules in clinic grew to 14 from 10.
- Expanded Lilly collaboration into immunology, cardiovascular, neuroscience; completed Vancouver HQ consolidation.
- Total liquidity over $875M ($670M cash + $205M government funding).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000162828024045022/0001628280-24-045022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000162828024045022/abcl-20241104.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-045022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer